scholarly journals A Network Integration Approach for Drug-Target Interaction Prediction and Computational Drug Repositioning from Heterogeneous Information

2017 ◽  
Author(s):  
Yunan Luo ◽  
Xinbin Zhao ◽  
Jingtian Zhou ◽  
Jinglin Yang ◽  
Yanqing Zhang ◽  
...  
Keyword(s):  
Heterogeneous Network ◽  
Drug Target ◽  
Large Scale ◽  
Molecular Mechanisms ◽  
Inflammatory Diseases ◽  
Drug Repositioning ◽  
Heterogeneous Data ◽  
Heterogeneous Information ◽  
Cox Inhibitors ◽  
New Drug

AbstractThe emergence of large-scale genomic, chemical and pharmacological data provides new opportunities for drug discovery and repositioning. Systematic integration of these heterogeneous data not only serves as a promising tool for identifying new drug-target interactions (DTIs), which is an important step in drug development, but also provides a more complete understanding of the molecular mechanisms of drug action. In this work, we integrate diverse drug-related information, including drugs, proteins, diseases and side-effects, together with their interactions, associations or similarities, to construct a heterogeneous network with 12,015 nodes and 1,895,445 edges. We then develop a new computational pipeline, called DTINet, to predict novel drug-target interactions from the constructed heterogeneous network. Specifically, DTINet focuses on learning a low-dimensional vector representation of features for each node, which accurately explains the topological properties of individual nodes in the heterogeneous network, and then predicts the likelihood of a new DTI based on these representations via a vector space projection scheme. DTINet achieves substantial performance improvement over other state-of-the-art methods for DTI prediction. Moreover, we have experimentally validated the novel interactions between three drugs and the cyclooxygenase (COX) protein family predicted by DTINet, and demonstrated the new potential applications of these identified COX inhibitors in preventing inflammatory diseases. These results indicate that DTINet can provide a practically useful tool for integrating heterogeneous information to predict new drug-target interactions and repurpose existing drugs. The source code of DTINet and the input heterogeneous network data can be downloaded from http://github.com/luoyunan/DTINet.

scholarly journals DLDTI: A learning-based framework for identification of drug-target interaction using neural networks and network representation

2020 ◽  
Author(s):  
Yihan Zhao ◽  
Kai Zheng ◽  
Baoyi Guan ◽  
Mengmeng Guo ◽  
Lei Song ◽  
...  
Keyword(s):  
Neural Networks ◽  
Drug Target ◽  
Large Scale ◽  
Molecular Mechanisms ◽  
Representation Learning ◽  
Heterogeneous Data ◽  
Biological Data ◽  
Mapping Space ◽  
Network Representation ◽  
Low Dimensional

AbstractTo elucidate novel molecular mechanisms of known drugs, efficient and feasible computational methods for predicting potential drug-target interactions (DTI) would be of great importance. A novel calculation model called DLDTI was generated for predicting DTI based on network representation learning and convolutional neural networks. The proposed approach simultaneously fuses the topology of complex networks and diverse information from heterogeneous data sources and copes with the noisy, incomplete, and high-dimensional nature of large-scale biological data by learning low-dimensional and rich depth features of drugs and proteins. Low-dimensional feature vectors were used to train DLDTI to obtain optimal mapping space and infer new DTIs by ranking DTI candidates based on their proximity to optimal mapping space. DLDTI achieves promising performance under 5-fold cross-validation with AUC values of 0.9172, which was higher than that of the method based on different classifiers or different feature combination technique. Moreover, biomedical experiments were also completed to validate DLDTI’s performance. Consistent with the predicted result, tetramethylpyrazine, a member of pyrazines, reduced atherosclerosis progression and inhibited signal transduction in platelets, via PI3K/Akt, cAMP and calcium signaling pathways. The source code and datasets explored in this work are available at https://github.com/CUMTzackGit/DLDTI

scholarly journals NeoDTI: Neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactions

2018 ◽  
Author(s):  
Fangping Wan ◽  
Lixiang Hong ◽  
An Xiao ◽  
Tao Jiang ◽  
Jianyang Zeng
Keyword(s):  
Drug Development ◽  
Biological Networks ◽  
Heterogeneous Network ◽  
Drug Target ◽  
Large Scale ◽  
Drug Repositioning ◽  
Supplementary Information ◽  
Functional Roles ◽  
Aggregation Techniques ◽  
Wide Range

AbstractMotivationAccurately predicting drug-target interactions (DTIs) in silico can guide the drug discovery process and thus facilitate drug development. Computational approaches for DTI prediction that adopt the systems biology perspective generally exploit the rationale that the properties of drugs and targets can be characterized by their functional roles in biological networks.ResultsInspired by recent advance of information passing and aggregation techniques that generalize the convolution neural networks (CNNs) to mine large-scale graph data and greatly improve the performance of many network-related prediction tasks, we develop a new nonlinear end-to-end learning model, called NeoDTI, that integrates diverse information from heterogeneous network data and automatically learns topology-preserving representations of drugs and targets to facilitate DTI prediction. The substantial prediction performance improvement over other state-of-the-art DTI prediction methods as well as several novel predicted DTIs with evidence supports from previous studies have demonstrated the superior predictive power of NeoDTI. In addition, NeoDTI is robust against a wide range of choices of hyperparameters and is ready to integrate more drug and target related information (e.g., compound-protein binding affinity data). All these results suggest that NeoDTI can offer a powerful and robust tool for drug development and drug repositioning.Availability and implementationThe source code and data used in NeoDTI are available at: https://github.com/FangpingWan/[email protected] informationSupplementary data are available at Bioinformatics online.

Lanthionine Synthetase Component C-Like Protein 2: A New Drug Target for Inflammatory Diseases and Diabetes

2014 ◽  
Vol 15 (6) ◽  
pp. 565-572 ◽  
Author(s):  
Pinyi Lu ◽  
Raquel Hontecillas ◽  
Casandra Philipson ◽  
Josep Bassaganya-Riera
Keyword(s):  
Drug Target ◽  
Inflammatory Diseases ◽  
New Drug ◽  
Component C

scholarly journals SDTRLS: Predicting Drug-Target Interactions for Complex Diseases Based on Chemical Substructures

Complexity ◽  
2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Cheng Yan ◽  
Jianxin Wang ◽  
Wei Lan ◽  
Fang-Xiang Wu ◽  
Yi Pan
Keyword(s):  
Computational Methods ◽  
Drug Target ◽  
Large Scale ◽  
High Efficiency ◽  
Drug Repositioning ◽  
External Validation ◽  
Complex Diseases ◽  
Biological Databases ◽  
Biomolecular Networks ◽  
New Chemical Entities

It is well known that drug discovery for complex diseases via biological experiments is a time-consuming and expensive process. Alternatively, the computational methods provide a low-cost and high-efficiency way for predicting drug-target interactions (DTIs) from biomolecular networks. However, the current computational methods mainly deal with DTI predictions of known drugs; there are few methods for large-scale prediction of failed drugs and new chemical entities that are currently stored in some biological databases may be effective for other diseases compared with their originally targeted diseases. In this study, we propose a method (called SDTRLS) which predicts DTIs through RLS-Kron model with chemical substructure similarity fusion and Gaussian Interaction Profile (GIP) kernels. SDTRLS can be an effective predictor for targets of old drugs, failed drugs, and new chemical entities from large-scale biomolecular network databases. Our computational experiments show that SDTRLS outperforms the state-of-the-art SDTNBI method; specifically, in the G protein-coupled receptors (GPCRs) external validation, the maximum and the average AUC values of SDTRLS are 0.842 and 0.826, respectively, which are superior to those of SDTNBI, which are 0.797 and 0.766, respectively. This study provides an important basis for new drug development and drug repositioning based on biomolecular networks.

scholarly journals Ensemble Learning Prediction of Drug-Target Interactions Using GIST Descriptor Extracted from PSSM-Based Evolutionary Information

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Xinke Zhan ◽  
Zhuhong You ◽  
Changqing Yu ◽  
Liping Li ◽  
Jie Pan
Keyword(s):  
Drug Target ◽  
Large Scale ◽  
Target Pair ◽  
Evolutionary Information ◽  
Support Vector ◽  
Svm Classifier ◽  
New Drug ◽  
Golden Standard ◽  
Scoring Matrix ◽  
G Protein Coupled

Identifying the drug-target interactions (DTIs) plays an essential role in new drug development. However, there still has the limited knowledge of DTIs and a significant number of unknown DTI pairs. Moreover, the traditional experimental methods have inevitable disadvantages such as high cost and time-consuming. Therefore, developing computational methods for predicting DTIs is attracting more and more attention. In this study, we report a novel computational approach for predicting DTI using GIST feature, position-specific scoring matrix (PSSM), and rotation forest (RF). Specifically, each target protein is first converted into a PSSM for retaining evolutionary information. Then, the GIST feature is extracted from PSSM and substructure fingerprint information is adopted to extract the feature of the drug. Finally, combining each protein and drug features to form a new drug-target pair, which is employed as input feature for RF classifier. In the experiment, the proposed method achieves high average accuracies of 89.25%, 85.93%, 82.36%, and 73.89% on enzyme, ion channel, G protein-coupled receptors (GPCRs), and nuclear receptor, respectively. For further evaluating the prediction performance of the proposed method, we compare it with the state-of-the-art support vector machine (SVM) classifier on the same golden standard dataset. These promising results illustrate that the proposed method is more effective and stable than other methods. We expect the proposed method to be a useful tool for predicting large-scale DTIs.

scholarly journals Drug2ways: Reasoning over causal paths in biological networks for drug discovery

2020 ◽  
Vol 16 (12) ◽  
pp. e1008464
Author(s):  
Daniel Rivas-Barragan ◽  
Sarah Mubeen ◽  
Francesc Guim Bernat ◽  
Martin Hofmann-Apitius ◽  
Daniel Domingo-Fernández
Keyword(s):  
Biological Networks ◽  
Large Scale ◽  
Molecular Mechanisms ◽  
Drug Repositioning ◽  
Underlying Disease ◽  
Pharmacological Intervention ◽  
Drug Candidate ◽  
Drug Candidates ◽  
Advanced Therapies ◽  
The Impact

Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats.

scholarly journals Drug2ways: Reasoning over causal paths in biological networks for drug discovery

2020 ◽  
Author(s):  
Daniel Rivas-Barragan ◽  
Sarah Mubeen ◽  
Francesc Guim Bernat ◽  
Martin Hofmann-Apitius ◽  
Daniel Domingo-Fernández
Keyword(s):  
Biological Networks ◽  
Large Scale ◽  
Molecular Mechanisms ◽  
Drug Repositioning ◽  
Underlying Disease ◽  
Pharmacological Intervention ◽  
Drug Candidate ◽  
Drug Candidates ◽  
Advanced Therapies ◽  
The Impact

AbstractElucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats.

scholarly journals Comparison of Target Features for Predicting Drug-Target Interactions by Deep Neural Network Based on Large-Scale Drug-Induced Transcriptome Data

Pharmaceutics ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 377 ◽  
Author(s):  
Hanbi Lee ◽  
Wankyu Kim
Keyword(s):  
Neural Network ◽  
Drug Target ◽  
Large Scale ◽  
Deep Neural Network ◽  
Structural Information ◽  
Drug Repositioning ◽  
Expression Profiles ◽  
Ppi Network ◽  
Drug Induced ◽  
Integrated Network

Uncovering drug-target interactions (DTIs) is pivotal to understand drug mode-of-action (MoA), avoid adverse drug reaction (ADR), and seek opportunities for drug repositioning (DR). For decades, in silico predictions for DTIs have largely depended on structural information of both targets and compounds, e.g., docking or ligand-based virtual screening. Recently, the application of deep neural network (DNN) is opening a new path to uncover novel DTIs for thousands of targets. One important question is which features for targets are most relevant to DTI prediction. As an early attempt to answer this question, we objectively compared three canonical target features extracted from: (i) the expression profiles by gene knockdown (GEPs); (ii) the protein–protein interaction network (PPI network); and (iii) the pathway membership (PM) of a target gene. For drug features, the large-scale drug-induced transcriptome dataset, or the Library of Integrated Network-based Cellular Signatures (LINCS) L1000 dataset was used. All these features are closely related to protein function or drug MoA, of which utility is only sparsely investigated. In particular, few studies have compared the three types of target features in DNN-based DTI prediction under the same evaluation scheme. Among the three target features, the PM and the PPI network show similar performances superior to GEPs. DNN models based on both features consistently outperformed other machine learning methods such as naïve Bayes, random forest, or logistic regression.

scholarly journals NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug–target interactions

2018 ◽  
Vol 35 (1) ◽  
pp. 104-111 ◽  
Author(s):  
Fangping Wan ◽  
Lixiang Hong ◽  
An Xiao ◽  
Tao Jiang ◽  
Jianyang Zeng
Keyword(s):  
Heterogeneous Network ◽  
Drug Target ◽  
New Drug ◽  
Neural Integration
Sign in / Sign up

Export Citation Format

Share Document